These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 19470527)
1. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Augustsson J; Neovius M; Cullinane-Carli C; Eksborg S; van Vollenhoven RF Ann Rheum Dis; 2010 Jan; 69(1):126-31. PubMed ID: 19470527 [TBL] [Abstract][Full Text] [Related]
2. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182 [TBL] [Abstract][Full Text] [Related]
3. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
4. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry. Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894 [TBL] [Abstract][Full Text] [Related]
5. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220 [TBL] [Abstract][Full Text] [Related]
6. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. Barra L; Pope JE; Payne M J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267 [TBL] [Abstract][Full Text] [Related]
7. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150 [TBL] [Abstract][Full Text] [Related]
8. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M; Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405 [TBL] [Abstract][Full Text] [Related]
9. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557 [TBL] [Abstract][Full Text] [Related]
10. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M Curr Med Res Opin; 2007 Aug; 23(8):1749-59. PubMed ID: 17588306 [TBL] [Abstract][Full Text] [Related]
11. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Finckh A; Simard JF; Gabay C; Guerne PA; Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288 [TBL] [Abstract][Full Text] [Related]
12. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis. Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR; Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821 [TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of TNF antagonists in routine clinical practice and costs]. Prokes M Vnitr Lek; 2009 Jan; 55(1):45-53. PubMed ID: 19227955 [TBL] [Abstract][Full Text] [Related]
15. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients. Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482 [TBL] [Abstract][Full Text] [Related]
16. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863 [TBL] [Abstract][Full Text] [Related]
17. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591 [TBL] [Abstract][Full Text] [Related]
18. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Carter CT; Changolkar AK; Scott McKenzie R J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040 [TBL] [Abstract][Full Text] [Related]
20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]